Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0005120
UniProt IDQ00403
Primary gene name(s)GTF2B
Synonym gene name(s)TF2B, TFIIB
Protein nameTranscription initiation factor IIB
Protein functionGeneral factor that plays a major role in the activation of eukaryotic genes transcribed by RNA polymerase II.
Subcellular locationNucleus.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q00403
Gene Ontology
(Biological Process)
Complete annatation
positive regulation of viral transcription [GO:0050434];
regulation of transcription, DNA-templated [GO:0006355];
snRNA transcription from RNA polymerase II promoter [GO:0042795];
transcription elongation from RNA polymerase II promoter [GO:0006368];
transcription from RNA polymerase II promoter [GO:0006366];
transcription initiation from RNA polymerase II promoter [GO:0006367];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
core promoter binding [GO:0001047];
thyroid hormone receptor binding [GO:0046966];
transcription factor binding [GO:0008134];
zinc ion binding [GO:0008270]
Gene Ontology
(Cellular Component)
Complete annatation
nucleolus [GO:0005730];
nucleoplasm [GO:0005654];
nucleus [GO:0005634]
Protein-protein interaction109214
Phylogenetic treeQ00403
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.7356419387354310.02542291388208960.0567413235644683
AZA vs. DISU0.1626681729697750.5211755230673320.940509006088293
AZA vs. IL70.1521621499612730.4311586616397310.999311006273513
AZA vs. SAHA0.03566507184422350.8845696495565990.974955946804153
DISU vs. CD3-0.5860912163960350.1068208937278480.196344122918373
DISU vs. IL7-0.01964261800281730.9379496320539040.988617459213365
DISU vs. SAHA-0.1255158621090090.6679462802256850.898933766732129
DMSO vs. AZA-0.1318971970064610.4352339463648561
DMSO vs. CD3-0.8770892378579770.006484393549103570.0171351322254421
DMSO vs. DISU-0.2959898844142720.226523429044340.738897851882729
DMSO vs. IL70.2909949704983760.107948546248270.591118489340503
DMSO vs. SAHA0.1603435543387580.4989667434713540.813436031515243
HIV vs. Mock in Activation-0.007199878364465630.9907632028347540.999983755607037
HIV vs. Mock in Latency0.07256464986223720.6628882943841510.999834320637052
IL7 vs. CD3-0.5757183503297030.0739693849210370.149998727151189
SAHA vs. CD3-0.7246256802039210.04202717883842750.0858895558848797
SAHA vs. IL7-0.119528451739810.6258524958235550.813721479975661
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.101303 0.544165
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.992 1.043 0.86 0.811 0.973
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1C9B X-ray 2.6Å A/E/I/M/Q=110-316.
1DL6 NMR - A=2-59.
1RLY NMR - A=1-60.
1RO4 NMR - A=1-60.
1TFB NMR - A=112-316.
1VOL X-ray 2.7Å A=113-316.
2PHG NMR - A=112-316.
5IY6 EM 7.2Å M=1-316.
5IY7 EM 8.6Å M=1-316.
5IY8 EM 7.9Å M=1-316.
5IY9 EM 6.3Å M=1-316.
5IYA EM 5.4Å M=1-316.
5IYB EM 3.9Å M=1-316.
5IYC EM 3.9Å M=1-316.
5IYD EM 3.9Å M=1-316.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat recruits 11080476
23827503
Vpr binds 8800208
9874563
10359081
15142377
15265780
15353294
19275580
20347598
21489275
Tat inhibited by 7608968
9292011
nucleocapsid enhances 10704334
Tat binds 9292011
Tat interacts with 7707527
77075288849451
9121429
238275039765201

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa03022 Basal transcription factors - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
Menu